About
Cancer Targeting Antibodies
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyChina
Clinical Trials (13)
View allTotal Trials
13
As Lead Sponsor
13
As Collaborator
0
Total Enrollment
1,303
By Phase
PHASE1/PHASE2: 10PHASE2: 1PHASE1: 2
By Status
RECRUITING: 5TERMINATED: 4NOT_YET_RECRUITING: 2WITHDRAWN: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline13 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT07112222Lead Sponsor
A Study of LM-350 in Subjects With Advanced Solid Tumours
PHASE1/PHASE2Not yet recruiting
55 participants
Started: Sep 30, 2025 · Completed: Jun 30, 2030
NCT06682780Lead Sponsor
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
PHASE1/PHASE2Recruiting
320 participants
Started: Sep 17, 2025 · Completed: Dec 1, 2029
NCT06868199Lead Sponsor
A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
PHASE1/PHASE2Recruiting
87 participants
Started: May 6, 2025 · Completed: Feb 1, 2028
NCT06873854Lead Sponsor
A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours
PHASE2Not yet recruiting
84 participants
Started: Mar 26, 2025 · Completed: Jan 26, 2030
NCT06650566Lead Sponsor
Study of LM-299 in Subjects Advanced Malignant Tumors
PHASE1/PHASE2Recruiting
108 participants
Started: Oct 9, 2024 · Completed: Jul 31, 2027
Locations (1)
Headquarters
Shanghai, China
Map
Loading map...